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Letters to the Editor
Coenzyme Q10
in Statin-Associated Myopathy
The excellent review by Macroff and Thompson titled “The role of
coenzyme Q10 on statin-associated myopathy” (1) concludes that
insufficient evidence exists for supplementation to treat or prevent
myopathy.
However, the authors recommend its use “if only via placebo
effect.” Should we not first be certain that statin-induced inhibition
of the farnesyl (and dolichol) pathways does not contribute to the
many pleiotropic benefits of statins before we attempt to “correct”
them?
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*Clinical Professor of Medicine
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Reply
Dr. Wolinsky raises an interesting issue. Statins block the rate-
limiting enzyme in the mevalonate pathway reducing cholesterol
production, but also reduce production of farnesyl and geranyl-
geranyl pyrophosphate. These molecules participate in post-
translational modification or prenylation of the Ras superfamily
guanosine triphosphatases or small G proteins. Small G proteins
are involved in cell signaling and proliferation. Statin inhibition of
these G proteins decreases vascular smooth muscle hypertrophy
and proliferation, improves endothelial function, and reduces
angiotensin I receptor expression (1). It may also explain the statin
antiarrhythmic effect in atrial fibrillation (2).
Coenzyme Q10 (Q10) supplementation should not affect small
G protein production since Q10 is not involved in the G protein
prenylation process. Furthermore, we recommended that Q10
supplementation be “tested” or “trialed” (3) only in statin myalgic
patients to allow ongoing statin treatment.
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Can Critically Short
Telomeres Cause Functional
Exhaustion of Progenitor Cells
in Postinfarction Heart Failure?
With great interest we read the article of Kissel et al. (1) on the
selective functional exhaustion of progenitor cells in patients with
ischemic cardiomyopathy (ICM) compared with nonischemic
dilated cardiomyopathy. As stated by the authors, obviously this
clinical study cannot disclose the potential mechanisms underlying
the functional impairment of progenitor cells. However, circum-
stantial evidence for a very reasonable explanation for the selective
exhaustion of (progenitor) cells in ICM could have been easily
obtained. Cells with telomeres reaching a critical length become
genomically unstable, become apoptotic, or enter replicative senes-
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cence (2,3). We recently reported in this Journal that telomere
length is reduced in patients with congestive heart failure but was
selectively reduced further in patients with ICM, as compared with
patients with nonischemic dilated cardiomyopathy (4). Moreover, as
Kissel et al. (1) observed a relationship with progenitor cell function
and New York Heart Association functional class, we observed a
relationship with telomere length and New York Heart Association
functional class. Consequently, we speculate that patients with ad-
vanced ICM are likely to have critically short telomeres in their
progenitor cells, leading to functional exhaustion (2). Considering the
fact that the group of Kissel et al. (1) has the know-how and ability to
perform in-depth research on telomeres, we are surprised that these
potentially very relevant mechanisms were not taken into account (5).
We strongly advocate probing this potentially very relevant mecha-
nism in future studies.
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Reply
We greatly appreciate the comment by Dr. Oeseburg and colleagues
hinting at a potential relationship between mean telomere length
(mTL) and functional exhaustion of hematopoietic progenitor cells.
Accordingly, we have reanalyzed data from 43 patients with conges-
tive heart failure (37 with ischemic cardiomyopathy and 6 with
nonischemic cardiomyopathy) from our bone marrow-mononuclear
cell (BM-MNC) study population (1), where we had simultaneously
determined mTL of peripheral blood cells. The mean age of this
subpopulation was 62  9 years, mean ejection fraction was 28 
8%, and mean N-terminal prohormone brain natriuretic peptide
serum levels were 1,850  2,727 ng/ml. We have chosen mTL
from peripheral blood granulocytes, which best reflects mTL of
bone marrow-residing CD34 stem cells (I. Spyridopoulos et al.,
personal communication, September 2007) (2) and compared it
with the colony-forming activity of BM-MNCs.
A significant correlation was found, as illustrated in Figure 1
(r  0.53, p  0.001), between mTL of granulocytes and
colony-forming capacity of BM-MNCs. Although age is the most
important determinant of telomere length, age did not correlate
with colony-forming activity in the present study cohort. In
addition, mTL of lymphocytes also demonstrated a significant
correlation with colony-forming capacity of BM-MNCs (r 
0.447, p  0.003). These data indeed suggest an association
between reduced “stem or progenitor cell” mTL and impaired
hematopoietic functionality of BM-MNCs.
Because of the limited sample size of our study, however, we
could not differentiate between ischemic and nonischemic etiology
of heart failure. We would also like to point out that telomere
length from granulocytes might not reflect mTL from the colony-
forming cells, which are just a small clonal subpopulation with
high proliferative potential.
In vivo data from patients after bone marrow transplantation
show that hematopoietic stem cells lose telomere length by further
division, leading to reduced proliferative potential (3). Experi-
ments in telomerase-deficient mice demonstrate that telomere
shortening leads to impaired mobilization of epidermal stem cells
and suppression of their clonogenic capacity (4). Our results would
indeed favor the hypothesis that telomere length has implications
on the functional capacity of hematopoietic progenitor cells in
patients with heart failure.
*Ioakim Spyridopoulos, MD
Christine K. Kissel, MD
Stefanie Dimmeler, PhD
Andreas M. Zeiher, MD
Figure 1 Telomere Length and Bone Marrow Function
Correlation of mean telomere length (mTL) of the granulocytes with colony-forming
capacity of bone marrow-derived mononuclear cells in patients with heart
failure. Dotted line indicates the linear regression curve.
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